Study guide

10.4 Migraine & Common Analgesics

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

10.4 Migraine & Common Analgesics

Key Takeaways Explain This Topic AI

Acute migraine care combines early analgesia (often NSAID/aspirin where suitable), triptans when indicated, and antiemetics for nausea — assess suitability before S3 triptan supply.

Medication-overuse headache is a major trap: frequent acute analgesic or triptan use can perpetuate headache; counsel limits and medical review.

Prophylaxis is considered for frequent, disabling, or overuse-prone migraine — agents are individualised (e.g. selected beta-blockers, amitriptyline, topiramate, candesartan, CGRP pathway medicines in specialist pathways).

Analgesic combinations increase efficacy for some acute pains but also increase overdose and adverse-effect complexity — check total paracetamol/opioid load.

Codeine-containing analgesics have tighter controls after Australian up-scheduling; aspirin is contraindicated in children/teenagers with viral illness because of Reye syndrome risk.

Last updated: August 2026

10.4 Migraine & Common Analgesics

Quick Answer: Treat migraine early with appropriate simple analgesics/NSAIDs , add a triptan when indicated (including careful S3 supply assessment ), and use antiemetics for nausea. Prevent medication-overuse headache by limiting frequent acute drug days. Know prophylaxis candidates at high level. Watch combination analgesics and codeine (post-rescheduling controls). Never give aspirin to children/teenagers with viral illness — Reye syndrome risk.

This section blends primary-care migraine management with everyday analgesic safety — classic Intern Written territory for 3.2 (implement) and 5.x primary care judgement integrated into therapeutics.

Migraine — recognise and differentiate (high-level)

Migraine is a primary headache disorder with recurrent attacks that may include moderate–severe pain, nausea/vomiting , photophobia/phonophobia , and sometimes aura (transient neurological symptoms). Red flags requiring urgent medical assessment include sudden “thunderclap” onset, neurological deficit unlike usual aura, fever/meningism, new headache in concerning ages/contexts, progressive daily headache, or headache after head injury — do not manage these as simple migraine at the counter .

Pharmacy goals in typical migraine:

Confirm it is consistent with the person’s known migraine pattern (or refer if first/worst/different).

Treat early in the attack.

Address nausea so oral medicines can work.

Reduce attack frequency through lifestyle and, when needed, prophylaxis referral.

Avoid analgesic overuse.

  • Acute migraine treatment
  • Simple analgesics and NSAIDs

For many mild–moderate attacks, soluble aspirin , ibuprofen , or paracetamol (alone or in evidence-based combinations where appropriate) taken early can help. Choose based on comorbidities (ulcer, CKD, CV disease, asthma, pregnancy). Avoid overuse patterns.

Triptans

Triptans (e.g. sumatriptan, rizatriptan, zolmitriptan, eletriptan, naratriptan) are 5-HT1B/1D agonists used for acute migraine when simple analgesia is insufficient. They are not for hemiplegic/basilar-type syndromes or for people with significant cardiovascular disease — contraindications matter .

S3 (Pharmacist Only) sumatriptan supply (where available under current scheduling and professional protocols) requires structured assessment concepts:

  • Assessment domain Examples of what pharmacists check
  • Diagnosis Established migraine diagnosis (not first undifferentiated severe headache)

Cardiovascular safety Ischaemic heart disease, uncontrolled hypertension, prior stroke/TIA, etc.

  • Other medicines Ergotamine, MAOIs, other triptans (timing rules), serotonergic load
  • Frequency High monthly use → consider medication-overuse and need for medical review/prophylaxis
  • Pregnancy / breastfeeding Refer to product information and medical advice

Counselling Take at headache onset (after aura settles per product advice), max doses/24 h, chest symptoms → medical care

If any exclusion or uncertainty applies, do not supply S3 — refer to a medical practitioner.

Antiemetics

Nausea impairs absorption and quality of life. Agents such as metoclopramide or prochlorperazine (status and counselling per schedule/product) are used in acute care pathways. Watch extrapyramidal reactions (especially in young people with metoclopramide), sedation, and interactions. Domperidone has cardiac rhythm cautions in some contexts — check AMH.

Non-oral routes

If vomiting is prominent, consider non-oral options (wafers, nasal sprays, injections in medical settings) rather than repeating oral doses that will not stay down.

Medication-overuse headache (MOH)

Medication-overuse headache occurs when acute headache medicines are used too frequently , perpetuating a chronic daily or near-daily headache pattern. Risk is classically discussed with:

  • Triptans (e.g. on ≥10 days/month patterns in teaching thresholds)
  • Combination analgesics / opioids
  • Simple analgesics used on most days (e.g. ≥15 days/month teaching thresholds)

Exact day-count thresholds are clinical teaching guides — the exam concept is that more acute medicine is not always better . Management involves medical review, education, and often withdrawal/reduction of the overused agent plus preventive strategies. Pharmacists should flag frequent repeat purchases and high triptan consumption for GP review.

Migraine prophylaxis — candidates (high-level)

Consider discussing prophylaxis (via GP/specialist) when attacks are frequent , disabling , poorly responsive to acute therapy, or associated with overuse risk . Examples of agents used in Australian practice (individualised; comorbidities decide choice):

  • Beta-blockers (e.g. propranolol, metoprolol) — avoid/caution in asthma, watch for bradycardia/fatigue
  • Amitriptyline — sedation, anticholinergic effects; useful if migraine + sleep/tension features

Topiramate — cognitive slowing, paraesthesia, weight loss, teratogenicity counselling, hydration/renal stone awareness

  • Candesartan — sometimes used; monitor blood pressure/renal issues
  • CGRP monoclonal antibodies / gepants — specialist/PBS pathway concepts; not casual OTC
  • Botulinum toxin for chronic migraine in specialist pathways

Lifestyle foundations: regular sleep, meals, hydration, trigger awareness, limit alcohol, manage stress, review hormonal triggers with the prescriber when relevant.

Common analgesic combinations

Combination products (paracetamol + ibuprofen; paracetamol + codeine historically; aspirin + codeine; migraine “cocktails”) can improve acute efficacy but:

Increase risk of exceeding paracetamol maxima when patients take multiple products.

Add opioid harms when codeine is included.

May accelerate medication-overuse if used frequently.

Always map the total daily load of each component. Prefer single-agent clarity when counselling complex patients.

Codeine-containing products — Australian post-rescheduling context

Australia up-scheduled codeine so that previously OTC codeine combination analgesics are no longer available without prescription (codeine became prescription-only). Exam implications:

Do not counsel as if low-dose codeine combos are freely available S2/S3 options.

Codeine is a prodrug converted by CYP2D6 to morphine — ultra-rapid metabolisers risk toxicity; poor metabolisers get little analgesia.

Harms include constipation, sedation, dependence, and overdose risk in combinations.

For cough or pain requests seeking “the old chemist codeine packs,” offer evidence-based alternatives , assess for misuse, and refer for medical review when appropriate.

Aspirin in children and Reye syndrome

Reye syndrome is a rare but serious condition with acute encephalopathy and hepatic injury, associated with aspirin use in children and teenagers during viral illnesses (notably influenza and varicella). Practical rule for community pharmacy:

Do not recommend aspirin for analgesic/antipyretic use in children/adolescents with viral illness.

Prefer paracetamol or ibuprofen (age/weight-appropriate products) when antipyresis/analgesia is needed and suitable.

Low-dose aspirin for specific medical indications (e.g. Kawasaki disease) is specialist-directed — not casual OTC use.

Integrated primary-care analgesic counselling

Whether for migraine or general pain, structure counselling as:

What is the pain likely to be, and are there red flags?

Which medicine matches the mechanism and patient risks?

How much and how often , including absolute maxima and duration caps?

What else — non-drug care, antiemetic need, prophylaxis referral, MOH prevention?

When to return/ escalate — lack of response, neurological change, overuse pattern, adverse effects.

Intern Written excellence here is not memorising every triptan half-life; it is demonstrating safe supply judgement , schedule awareness , and public-health sense about overuse and paediatric aspirin.